Whether you’re newly diagnosed or wanting to explore new treatments, SRF Carebox Connect provides the resources you need to find trials that could be the right fit for you. SRF...
Read More
Last week, the CONQUEST team headed to Argentina to connect with local physicians! CONQUEST is a global platform clinical trial created by the Scleroderma Research Foundation to accelerate the development...
Read More
Boehringer Ingelheim has announced that its Phase III FIBRONEER-ILD trial examining nerandomilast met its primary endpoint, measuring lung function through forced vital capacity (FVC) at 52 weeks. While nerandomilast remains...
Read More
Rare Disease Day is coming soon—a time to shine a light on the millions of people living with rare diseases, like scleroderma. At the Scleroderma Research Foundation (SRF), we believe...
Read More
Navigating clinical trials can feel overwhelming, but finding accurate, reliable information shouldn’t be. Our new clinical trial page is designed to empower you with resources and support to make informed...
Read More
Navigating clinical trials can feel overwhelming, but finding accurate, reliable information shouldn’t be. Our new clinical trial page is designed to empower you with resources and support to make informed...
Read More
The goal of all clinical trials is to be as inclusive as possible. However, it is necessary to develop specific inclusion and exclusion criteria. The reason for this is to...
Read More
San Francisco, CA (June 25, 2024)—CONQUEST, a highly innovative platform clinical trial conceived of and led by the Scleroderma Research Foundation (SRF) and designed to rapidly advance promising treatments for...
Read More
CONQUEST Featured in "Endpoints News" SRF Chairman of the Board Luke Evnin, PhD, recently sat down with Andrew Dunn of "Endpoints News" to announce that CONQUEST has received FDA OK...
Read More
SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
